REAL WORLD EVIDENCE: EFFECTIVENESS OF ALFUZOSIN IN BENIGN PROSTATIC HYPERPLASIA
Dr. Praveen R.* and Dr. Kumar T. N.
Background/Objectives: To evaluate the effectiveness and safety of Alfuzosin - An uroselective Alpha blocker in patients with Benign Prostatic Hyperplasia. Materials and Methods: A prospective, open labelled study among thirty patients with Benign Prostatic Hyperplasia (BPH) where the symptoms of Benign Prostatic Hyperplasia (BPH) were accessed and graded as per standard questionnaire i.e International Prostatic Symptomatic Score(IPSS). A standard performa was made to capture the general physical examination, vital signs i.e blood pressure, heart rate, systemic examination such as cardiovascular system and abdomen examination including digital per rectal examination. Laboratory investigations included random blood sugar, prostate specific antigen and urine analysis. The ultrasonography investigations were done to measure the size of prostate and to assess the post void residual urine. The uroflow meter analysis was done as an OPD procedure. The patient was advised to come up for follow visit at first and third months. Results: In our study, patients on Alfuzosin 10 mg once daily showed a significant improvement in post void residual urine, uroflow rates and symptomatic score(IPSS). The improvement in the above parameters was found to be statistically significant from first month onwards and the improvement persisted till end of the study. The drug is safe and well tolerated. Interpretation/conclusion: Alfuzosin has been found to be a safe option in medical management of Benign Prostatic Hyperplasia.
Keywords: Alfuzosin; Benign prostatic hyperplasia; Post void residual urine.
[Full Text Article]